TABLE 3.

Adverse events

	Total (n = 50)		KRD (n = 31)		KD (n = 19)		p
	All	G3‐4	All	G3‐4	All	G3‐4	All	G3‐4
Hematological adverse events, n (%)
Anemia	32 (64.0)	10 (20.0)	20 (64.5)	5 (16.1)	12 (63.2)	5 (26.3)	1	.474
Lymphopenia	30 (60.0)	21 (42.0)	18 (58.1)	10 (32.3)	12 (63.2)	10 (52.6)	.774	.255
Thrombocytopenia	25 (50.0)	13 (26.0)	13 (41.9)	9 (29.0)	12 (63.2)	5 (26.3)	.255	1
Neutropenia	23 (46.0)	12 (24.0)	12 (38.7)	8 (25.8)	11 (57.9)	4 (21.1)	.383	1
Non‐hematological adverse events, n (%)
Hypertension	21 (42.0)	3 (6.0)	11 (35.5)	0	10 (52.6)	3 (15.8)	.255	.049
Fever	12 (24.0)	0	7 (22.6)	0	5 (26.3)	0	1	‐
Fatigue	12 (24.0)	2 (4.0)	6 (19.4)	1 (3.2)	6 (31.6)	1 (5.3)	.496	1
Infection	8 (16.0)	3 (6.0)	4 (12.9)	1 (3.2)	4 (21.1)	2 (10.5)	.459	.549
Skin rash	7 (14.0)	1 (2.0)	5 (16.1)	1 (3.2)	2 (10.5)	0	.229	1
Arrhythmia	7 (14.0)	0	3 (9.7)	0	4 (21.1)	0	.404	‐
AST/ALT* increased	5 (10.0)	3 (6.0)	2 (6.5)	1 (3.2)	3 (15.8)	2 (10.5)	.355	.549
Constipation	5 (10.0)	0	3 (9.7)	0	2 (10.5)	0	1	‐
QTc interval prolonged	5 (10.0)	0	4 (12.9)	0	1 (5.3)	0	.637	‐
Anorexia	4 (8.0)	1 (2.0)	1 (3.2)	0	3 (15.8)	1 (5.3)	.147	.380
Diarrhea	4 (8.0)	0	2 (6.5)	0	2 (10.5)	0	.618	‐
Thrombosis	4 (4.0)	1 (2.0)	3 (9.7)	1 (3.2)	1 (5.3)	0	.255	1
Hypoxia	3 (6.0)	3 (6.0)	1 (3.2)	1 (3.2)	2 (10.5)	2 (10.5)	.549	.549
Nausea	3 (6.0)	0	0	0	3 (15.8)	0	.049	‐
Edema	3 (6.0)	0	1 (3.2)	0	2 (10.5)	0	.549	‐
Peripheral neuropathy	3 (6.0)	0	2 (6.5)	0	1 (5.3)	0	1	‐
Delirium	3 (6.0)	2 (10.5)	0	0	3 (15.8)	2 (10.5)	.049	.140
Dyspnea	2 (4.0)	2 (4.0)	0	0	2 (10.5)	2 (10.5)	.140	.140
Pulmonary edema	1 (2.0)	1 (2.0)	0	0	1 (5.3)	1 (5.3)	1	1
Heart failure	1 (2.0)	0	1 (3.2)	0	0	0	.380	‐
ST segment elevation	1 (2.0)	0	1 (3.2)	0	0	0	.380	‐